This is a working overview of monohydrate, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-24. Anything still debated is marked as such rather than presented as settled.
Sourcing and verification of creatine monohydrate involve both manufacturing origin and third-party testing. Industrial production commonly starts with sarcosine and cyanamide, followed by crystallization to obtain the monohydrate. Some products are derived from animal sources, while others are synthesized from non-animal precursors. Certificates of analysis report assay, heavy metals, and microbial limits. Regulations differ by country: in the United States it is sold as a dietary supplement, whereas in the European Union it falls under food supplement rules.
In solid form, creatine monohydrate is relatively stable when kept dry and away from heat. Moisture and elevated temperatures promote cyclization into creatinine, a related compound with no role in the phosphagen system. Degradation accelerates in aqueous solution, where the conversion can occur within hours to days depending on pH and temperature. Manufacturers typically recommend storage in sealed containers at room temperature, with relative humidity below 50 percent. Long-term stability data for opened containers are limited.
Analytical methods for creatine monohydrate focus on identity, purity, and degradation products. High-performance liquid chromatography with ultraviolet detection is common, often at a wavelength near 210 nanometers. Titration and nuclear magnetic resonance spectroscopy can also quantify the parent compound. Pharmacopeial monographs specify tests for appearance, solubility, water content, and related substances, including creatinine. Purity values above 99 percent are typical for pharmaceutical-grade material, though supplement-grade products vary. Independent verification can detect label discrepancies.
In animals, creatine is synthesized mainly in liver, kidney, and pancreas from arginine, glycine, and methionine. The first committed step transfers a guanidino group from arginine to glycine, forming guanidinoacetate. Subsequent methylation by S-adenosylmethionine yields creatine. Dietary sources include meat and fish; endogenous synthesis supplies part of the body pool. Most creatine is stored in skeletal muscle, where it is converted to phosphocreatine and participates in rapid regeneration of adenosine triphosphate during short, intense activity.
Commercial creatine products appear in several forms, including monohydrate, hydrochloride, citrate, nitrate, and ethyl ester. Creatine monohydrate is the most studied form and serves as a reference material in comparative research. Different forms vary in solubility, pH, and water content, but they share creatine as the active moiety after dissolution. Claims that one form is uniformly superior remain debated, and study designs often differ in population, exercise protocol, and outcome measures. Purity and hydration state are central to interpreting product labels.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | 15–25 °C | Cool, dry, away from moisture |
| Relative humidity | < 50% | High humidity promotes degradation |
| Primary degradation product | Creatinine | Formed via cyclization, especially in solution |
| Common analytical method | HPLC-UV | Often at 210 nm; also titration or NMR |
| Shelf life (solid) | 2–3 years | When kept sealed and dry; varies by manufacturer |
Creatine monohydrate is a crystalline compound formed from creatine and one molecule of water. Creatine itself is a nitrogen-containing organic acid that occurs in vertebrate muscle and other tissues. The monohydrate designation refers to the water included in the crystal lattice, not to water added during manufacturing. Its chemical formula is commonly written as C4H9N3O2·H2O. The solid is typically a white, odorless powder with low solubility in water at room temperature. It is one of several creatine forms described in scientific and commercial literature.
The compound was identified in the nineteenth century after chemists isolated a nitrogenous substance from meat extracts. Later work established its role in muscle energy metabolism and its conversion to phosphocreatine. Chemical synthesis of creatine followed, and industrial production made the monohydrate widely available as a purified powder. Interest expanded in the late twentieth century when researchers began studying creatine supplementation and muscle physiology. Historical accounts sometimes differ on exact dates and attributions, but the broad sequence from tissue extracts to synthetic production is well documented.
In the body, creatine is synthesized from arginine, glycine, and methionine, mainly in the liver and kidneys, and is also obtained from foods such as meat and fish. About 95% of body creatine is stored in skeletal muscle, where a fraction is phosphorylated to phosphocreatine. Phosphocreatine serves as a rapid reserve of high-energy phosphate for short bursts of ATP regeneration. The monohydrate form supplies creatine after dissolution and absorption, but it is not itself the active phosphorylated species.
Creatine was first identified in skeletal muscle extracts in the nineteenth century, and its role in phosphagen energy buffering was clarified in the twentieth century. The monohydrate salt became widely studied after methods for inexpensive synthesis and crystallization were developed. Modern research examines its effects on muscle energetics, recovery, and cognitive performance under specific conditions. Findings vary with population, exercise protocol, baseline creatine status, and measurement method. Studies often compare supplementation with placebo during controlled training or testing schedules.
Creatine monohydrate is a hydrated form of creatine, a nitrogen-containing compound involved in cellular energy metabolism. Its molecular formula is C4H9N3O2·H2O, with a molar mass around 149.15 g/mol. The monohydrate is the most common solid form used in research and commercial settings because it crystallizes readily and remains stable under ordinary conditions. The term monohydrate indicates one water molecule per creatine molecule in the crystal lattice. It appears as a white crystalline powder with low odor.
As shown above, E. coli can grow with reducing agents such as formate, hydrogen, or lactate as electron donors, and nitrate, DMSO, or oxygen as acceptors. The larger the difference in midpoint potential between an oxidizing and reducing agent, the more energy is released when they react. Out of these compounds, the succinate/fumarate pair is unusual, as its midpoint potential is close to zero. Succinate can therefore be oxidized to fumarate if a strong oxidizing agent such as oxygen is available, or fumarate can be reduced to succinate using a strong reducing agent such as formate. These alternative reactions are catalyzed by succinate dehydrogenase and fumarate reductase, respectively. Some prokaryotes use redox pairs that have only a small difference in midpoint potential. For example, nitrifying bacteria such as Nitrobacter oxidize nitrite to nitrate, donating the electrons to oxygen. The small amount of energy released in this reaction is enough to pump protons and generate ATP, but not enough to produce NADH or NADPH directly for use in anabolism. This problem is solved by using a nitrite oxidoreductase to produce enough proton-motive force to run part of the electron transport chain in reverse, causing complex I to generate NADH. Prokaryotes control their use of these electron donors and acceptors by varying which enzymes are produced in response to environmental conditions. This flexibility is possible because different oxidases and reductases use the same ubiquinone pool.
The two substrates of this enzyme are sulcatol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are sulcatone, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is sulcatol:NAD+ oxidoreductase.
=== Private and public key generation === A cryptocurrency wallet works by random number being generated. The number is converted to a private key using the specific requirements of the cryptocurrency. A public key is then generated from the private key. This private key is used by the owner to access and send cryptocurrency, while the public key can be shared to any third party to receive cryptocurrency. Up to this stage no computer or electronic device is required and all key pairs can be mathematically derived and written down by hand. The private key and public key pair (known as an address) are not known by the blockchain or anyone else. The blockchain will only record the transaction of the public address when cryptocurrency is sent to it, thus recording in the blockchain ledger the transaction of the public address.
Ronald E. Blaylock, Managing Partner of GenNx360 Capital Partners Albert Bourla, CEO of Pfizer Mortimer J. Buckley, former CEO of The Vanguard Group Sue Desmond-Hellmann, former CEO of The Bill and Melinda Gates Foundation Joseph J. Echevarria, former CEO of Deloitte LLP Scott Gottlieb, former Commissioner of the FDA Helen Hobbs, Professor at the University of Texas Southwestern Medical Center Susan Hockfield, 16th President of the Massachusetts Institute of Technology Dan Littman, professor of Molecular Immunology at New York University Shantanu Narayen, CEO of Adobe Suzanne Nora Johnson, former Vice Chairman of Goldman Sachs James Quincey, CEO of The Coca-Cola Company James C. Smith, former CEO of Thomson Reuters Cyrus Taraporevala, former president and CEO of State Street Global Advisor
Sources: en.wikipedia.org
=== JINR–LLNL collaboration === The now-confirmed discovery of element 114 was made in June 1999 when the JINR team repeated the first 244Pu + 48Ca reaction from 1998; following this, the JINR team used the same hot fusion technique to synthesize elements 116 and 118 in 2000 and 2002 respectively via the 248Cm + 48Ca and 249Cf + 48Ca reactions. They then turned their attention to the missing odd-numbered elements, as the odd protons and possibly neutrons would hinder decay by spontaneous fission and result in longer decay chains. The first report of element 113 was in August 2003, when it was identified as an alpha decay product of element 115. Element 115 had been produced by bombarding a target of americium-243 with calcium-48 projectiles. The JINR–LLNL collaboration published its results in February 2004:
The fungus is highly toxic, and is responsible for the majority of fatal mushroom poisonings worldwide. Its biochemistry has been researched intensively for decades, and 30 grams (1.1 ounces), or half a cap, of this mushroom is estimated to be enough to kill a human. On average, one person dies a year in North America from death cap ingestion. The toxins of the death cap mushrooms primarily target the liver, but other organs, such as the kidneys, are also affected. Symptoms of death cap mushroom toxicity usually occur 6 to 12 hours after ingestion. Symptoms of ingestion of the death cap mushroom may include nausea and vomiting, which is then followed by jaundice, seizures, and coma, which will lead to death. The mortality rate of ingestion of the death cap mushroom is believed to be around 10–30%. Some authorities strongly advise against putting suspected death caps in the same basket with fungi collected for the table and to avoid even touching them. Furthermore, the toxicity is not reduced by cooking, freezing, or drying. Poisoning incidents usually result from errors in identification. Recent cases highlight the issue of the similarity of A. phalloides to the edible paddy straw mushroom (Volvariella volvacea), with East and Southeast Asian immigrants in Australia and the West Coast of the U.S. falling victim. In an episode in Oregon, four members of a Korean family required liver transplants. Many North American incidents of death cap poisoning have occurred among Laotian and Hmong immigrants, since it is easily confused with A.
Grade 3 or 4 internal rectal prolapse (as per Oxford rectal prolapse grade), PLUS Symptoms of obstructed defecation or fecal incontinence which are reducing quality of life, PLUS Failure of non surgical treatments to sufficiently control symptoms. Pain caused by associated solitary rectal ulcer syndrome is another indication. IRP which coexists with large rectocele or enterocele, where non surgical treatments or simple perineal procedures have failed.
Sources: en.wikipedia.org
Heterocodeine (6-methoxymorphine) is an opiate derivative, the 6-methyl ether of morphine, and a structural isomer of codeine; it is called "hetero-" because it is the reverse isomer of codeine. Heterocodeine was first synthesised in 1932 and first patented in 1935. It can be made from morphine by selective methylation. Codeine is the natural mono-methyl ether, but must be metabolized for activity (that is, it is a prodrug). In contrast the semi-synthetic mono-methyl ether, heterocodeine is a direct agonist. The 6,7,8,14 tetradehydro 3,6 methyl di-ether of morphine is thebaine. Heterocodeine is 6 times more potent than morphine due to having a substitution at the 6-hydroxy position, in a similar manner to 6-acetylmorphine. The drug methyldihydromorphine (dihydroheterocodeine) is a derivative of heterocodeine. Like the morphine metabolite morphine-6-glucuronide, 6-position branches (esters or ethers) of morphine bind to the otherwise unagonized human mu receptor subtype mu-3 (or μ3); as well as the 6-acetylmorphine metabolite of heroin this includes heterocodeine. The relative strength of heterocodeine to codeine has been published as 50, 72, 81, 88, 93, 96, and 108 ×. It is not mentioned specifically in the Controlled Substances Act 1970 but is a Schedule II controlled substance as an analogue of morphinan or morphine under the morphine structure rules of the Analogues Act; in other countries it is usually controlled as a strong opioid. Homocodeine is a synonym for pholcodine.
== Operations == Hetero Group employs over 30,000 people and has operations in 145+ countries. Hetero Group’s subsidiaries include Hetero Healthcare and Hetero Research Foundation, and also foreign subsidiaries such as Camber Pharmaceuticals in the United States and Southeast Asia, Amarox Pharma Global in Europe and GCC, and Seven Pharma in Latin America. Hetero also operates Asia's Largest API SEZ manufacturing complex for APIs, with over 1000 reactors.
In 1956, a factory in the city released methylmercury in the industrial wastewater resulting in thousands of deaths and many other health problems. This incident alerted the world to the phenomenon of bioaccumulation. While all mercury compounds are toxic, organomercury compounds are especially dangerous because they are readily absorbed from the skin and can cross the blood–brain barrier to cause irreversible brain damage. Methylmercury and related compounds are thought to bind to the sulfur of cysteinyl residues in proteins. Nickel causes a contact dermatitis in up to 20% of people as result of prolonged contact with coins or jewelry. Industrial processing with highly toxic nickel carbonyl can cause acute poisoning; inhalation of nickel and nickel compounds in these settings can cause respiratory tract cancer. Chromium, arsenic, cadmium, mercury, and lead have a strong affinity for sulfur; in the human body they usually bind, via thiol groups (–SH), to enzymes responsible for controlling the speed of metabolic reactions. The resulting sulfur-metal bonds inhibit the proper functioning of the enzymes involved; human health deteriorates, sometimes fatally.
==== Antigonadotropic effects ==== Changes in endogenous testosterone levels may also contribute to differences in myotrophic–androgenic ratio between testosterone and synthetic AAS. AR agonists are antigonadotropic – that is, they dose-dependently suppress gonadal testosterone production and hence reduce systemic testosterone concentrations. By suppressing endogenous testosterone levels and effectively replacing AR signaling in the body with that of the exogenous AAS, the myotrophic–androgenic ratio of a given AAS may be further, dose-dependently increased, and this hence may be an additional factor contributing to the differences in myotrophic–androgenic ratio among different AAS. In addition, some AAS, such as 19-nortestosterone derivatives like nandrolone, are also potent progestogens, and activation of the progesterone receptor (PR) is antigonadotropic similarly to activation of the AR. The combination of sufficient AR and PR activation can suppress circulating testosterone levels into the castrate range in men (i.e., complete suppression of gonadal testosterone production and circulating testosterone levels decreased by about 95%). As such, combined progestogenic activity may serve to further increase the myotrophic–androgenic ratio for a given AAS.
Sources: en.wikipedia.org
Yes, especially when exposed to moisture or heat, where it converts to creatinine. In dry, sealed containers at room temperature, degradation is slow and the product may remain within specification for two to three years.
Common methods include high-performance liquid chromatography, titration, and nuclear magnetic resonance spectroscopy. These techniques quantify the parent compound and detect related substances such as creatinine.
Keep the powder in a tightly sealed container in a cool, dry place, ideally between 15 and 25 degrees Celsius with low humidity. Avoid storing aqueous solutions for extended periods because degradation occurs faster in solution.
Creatine is the base compound, while creatine monohydrate includes one water molecule per creatine molecule in its crystal structure. The monohydrate form is common in supplements and analytical standards. The body uses creatine itself after the water is removed or dissociated.